【摘 要】
：
Accumulating evidences have showed that pharmacokinetics of some drugs was altered by diabetes mellitus, leading to changes of pharmacodynamic/toxic effects.Pro-dosage prediction ofpharmacokinetics wa
【机 构】
：
Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, Nanjing,Chi
【出 处】
：
第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu
论文部分内容阅读
Accumulating evidences have showed that pharmacokinetics of some drugs was altered by diabetes mellitus, leading to changes of pharmacodynamic/toxic effects.Pro-dosage prediction ofpharmacokinetics was needed for appropriate optimization of dose for diabetic patients.Aim of study was to develop a novel physiologically based pharmacokinetic (PBPK) model for predicting pharmacokinetics of drugs in type 2 diabetic patients quantitatively.
其他文献
目的 依托药物重整手段，利用治疗药物监测和基因检测技术，探索临床药师干预门诊随访的肾移植受者免疫抑制剂方案由环孢素切换为他克莫司的工作切入点。方法 临床药师以1例长期忠有严重便秘的肾移植受者的环孢素血药浓度异常波动为切入点，对其临床资料和药物信息进行重整和分析后，建议停用大黄碳酸氢钠片治疗便秘和将环孢素切换为他克莫司；根据受者携带CYP3A5*3/*3基因型和治疗药物监测结果，制定和优化他克莫司给
目的 万古霉素治疗药物监测的必要性一直备受争议,该研究旨在系统评价关于万古霉素治疗药物监测必要性的证据.方法 计算机检索Medline,Embase,Web of Sciences,Cochrane图书馆、CNKI和CBM,纳入所有比较万古霉素治疗药物监测和不进行万古霉素治疗药物监测对临床结局的作用的随机对照研究和观察性研究,检索时间截至3月29号.由2位评价者按照纳入和排除标准独立选择相关研究,
目的 了解免疫抑制剂他克莫司不良反应的总体情况，综合评估其临床应用的安全性，并针对可能引起不良反应的主要相关因素进行探讨。方法 检索维普中文科技期刊数据库、万方数据库及中国期刊全文数据库(2000～2013年)的他克莫司不良反应相关文献，对患者性别、年龄、他克莫司血药浓度、不良反应发生时问、临床表现、处置及转归进行汇总，最后对引起不良反应的诱发因素进行分析和讨论。结果 共纳入中文文献37篇，涉及病
目的：建立丙戊酸(Valproic acid,VPA)在中国癫痫忠儿体内的群体药物动力学模型,基于模型采用贝易斯反馈法制定个体化的给药方案.方法：回顾性收集2011年5月至2013年5月在北京天坛医院住院并服用VPA常规治疗癫痫患儿的临床资料与血药浓度数据,采用非线性混合效应模型法(nonlinear mixed effect modeling,NONMEM)建立丙戊酸在上述人群中的群体药物动力学
Objective To explore the relationship between single nucleotide polymorphisms (SNP) of dihydropyrimidine dehydrogenase (DPD) and chemotherapeutic toxicity of 5-Fluorouracil (5-Fu) in patients with gas
OBJECTIVE The present study was aimed to evaluate whether the interindividual variation of cyclosporine dosages and blood concentration were associated with CYP3A4 and CYP3A5 polymorphism in renal tra
OBJECTIVE:To realize personalized medicine on the basis of population pharmacokinetics (PopPK) of valproic acid (VPA) in children with epilepsy.METHODS:The clinical data and VPA plasma concentrations
Objective: The objective of this study is to estimate the population pharmacokinetics of voriconazole, to identify the factors influencing voriconazole pharmacokinetics, and to identify optimal dosage
Aim:Todevelop and validate a general physiologicallybased pharmacokinetic (PBPK) model for hepatic pathway in Chinese adults at various ages, and to evaluate it with midazolam (substrate of CYP3A4) as
Objective:Icotinib is a potent small-molecule inhibitor of epidermal growth factor receptor (EGFR)-tyrosine kinase (TKI), which was designed for the treatment of non-small cell lung cancer (NSCLC).It